Neuroscience CE Activities

Neuroscience blog

View Details

Improving the Management of Chronic Neurodegenerative Diseases with Interprofessional Collaboration & Care

Multiple sclerosis (MS) and Parkinson’s disease (PD) are 2 highly prevalent chronic progressive neurodegenerative disorders. Over time, the accumulation and subsequent worsening of the symptoms associated with these diseases can result in disability, impaired quality of life, loss of independence, and an increased burden on caregivers.  
View Details

New Treatments for SMA: Should We Offer Them to Adults?

Spinal muscular atrophy (SMA) is a genetic disorder and a devastating diagnosis for children and their families that can lead to death or a lifetime of severe disability and progressively limited mobility.

RMEI DECISION SUPPORT AIDS

View Details

The Evolving Role of Orexin-Based Therapy in Narcolepsy Type 1 Management

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
View Details

Clearing the Path for the Accurate Diagnosis and Optimal Treatment of Bipolar Depression: A Clinical Convergence®

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

LATEST NEUROSCIENCE ARTICLES

RSS Latest Neuroscience Articles
  • Homozygosity for R47H in TREM2 and the Risk of Alzheimer’s Disease June 20, 2024
    A meta-analysis of tests of association between variants in TREM2 and Alzheimer’s disease showed high risk among R47H homozygotes.
    Hreinn Stefansson, G. Bragi Walters, Gardar Sveinbjornsson, Vinicius Tragante, Gudmundur Einarsson, Hannes Helgason, Asgeir Sigurðsson, Doruk Beyter, Audunn S. Snaebjarnarson, Erna V. Ivarsdottir, Gudmar Thorleifsson, Bjarni V. Halldorsson, Gudmundur Norddahl, Unnur Styrkarsdottir, Arni Sturluson, Hilma Holm, Agnar Helgason, Kristjan Moore, Hannes P. Eggertsson, Asmundur H. Oddsson, Gudrun A. Jonsdottir, Arni F. Gunnarsson, Gyda Bjornsdottir, Rosa S. Gisladottir, Thorgeir E. Thorgeirsson, Astros Skuladottir, Daniel F. Gudbjartsson, Patrick Sulem, Palmi Jonsson, Steinunn Thordardottir, Jon Snaedal, Helga Eyjolfsdottir, Byron Creese, Clive Ballard, Anne Corbett, Miguel Vasconcelos Da Silva, Dag Aarsland, Ole A. Andreassen, Geir Selbæk, Srdjan Djurovic, Eystein Stordal, Thormod Fladby, Jan Haavik, Jannicke Igland, Lasse M. Giil, Sture Eriksson, Göran Hallmans, Hugo Lövheim, Karin Lopatko Lindman, Miles Trupp, Lars Forsgren, Thomas Werge, Karina Banasik, Søren Brunak, Henrik Ullum, Ruth Frikke-Schmidt, Sisse R. Ostrowski, Maria Didriksen, Erik Sørensen, Anja H. Simonsen, Jørgen E. Nielsen, Gunhild Waldemar, Ole B. Pedersen, Christian Erikstrup, Kirk U. Knowlton, Lincoln D. Nadauld, Kari Stefansson, for the DemGen Study Group*, for the DBDS Genomic Consortium*
  • Fundamentals of Medical Ethics: Ethics and Highly Innovative Research on Brain Diseases June 20, 2024
    Despite exciting advances, conducting brain research and appropriately implementing interventions or insights derived from it raise both familiar and new ethical challenges.
    Saskia Hendriks, Christine Grady
  • Protection against Alzheimer’s Disease with APOE Christchurch Variant — How? June 20, 2024
    Protective variants of genetic loci are of particular interest for two reasons: first, because they are important from a clinical genetic perspective; and second, because they may give mechanistic clues about potential therapeutic strategies. In Alzheimer’s disease, the most prevalent protective allele is APOE2 (encoding apolipoprotein E2), which...
    John Hardy

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.